Organon & Co. is voluntarily supplementing its Definitive Proxy Statement following a lawsuit filed in New Jersey alleging that merger disclosures were materially incomplete and misleading. The supplement includes updated synergy estimates of approximately $700 million and financial projections for revenue and Adjusted EBITDA through 2030. Organon & Co. is a pharmaceutical company specializing in women's health and established brands.
